TS
PLRX icon

Thomas Steyer’s Pliant Therapeutics PLRX Stock Holding History

Thomas Steyer’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-490,000
Closed -$14.3M – 309
2021
Q2 		$14.3M Sell
490,000
-274,262
-36% -$8.54M 0.06% 116
2021
Q1 		$30.1M Hold
764,262
– – 0.15% 87
2020
Q4 		$17.4M Hold
764,262
– – 0.1% 92
2020
Q3 		$17.3M Sell
764,262
-86,539
-10% -$2.16M 0.12% 88
2020
Q2 		$27.6M Buy
+850,801
New +$22.6M 0.22% 77

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Thomas Steyer's PLRX Position: Q3 2021 in Review

Thomas Steyer sold out of Pliant Therapeutics (PLRX) in Q3 2021, closing a stake of 490,000 shares — an estimated $14.3M sold.

Thomas Steyer first reported a position in PLRX in Q2 2020 and held it in 5 quarters. The position peaked at $30.1M in Q1 2021. 77 funds tracked by Wall St. Rank hold PLRX as of Q3 2021.

  • Thomas Steyer reported no remaining Pliant Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Thomas Steyer sold 490,000 Pliant Therapeutics shares in Q3 2021, an estimated $14.3M.
  • Thomas Steyer first reported a position in Pliant Therapeutics in Q2 2020 and held it in 5 quarters.
  • Thomas Steyer's Pliant Therapeutics position peaked at $30.1M in Q1 2021.
  • 77 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2021.

Based on Farallon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.